The price-to-earnings ratio has its supporters and detractors, but this simple statistic can be an easy way for investors to gauge how cheap an average stock is on the fly. For some stocks, however, the P/E ratio is a misleading statistic -- particularly when earnings betray a poor business model. With stocks' rise this year and earnings on the upswing, however, is the P/E ratio a suitable fit in the medical device industry, particularly as many device stocks have soared in 2013?
Using data compiled by stock screening site Finviz.com, here are three of the cheapest medical device stocks in the industry as sorted by the P/E ratio. Are these picks worth your investment -- or is this simple statistic hiding lagging financials and flailing companies? Motley Fool contributor Dan Carroll tells you what you need to know about the device industry's cheapest pickings below.
While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of.�Click here now�to keep reading.
Best Solar Companies To Own In Right Now: Legacy Reserves LP(LGCY)
Legacy Reserves LP, an independent oil and natural gas limited partnership, engages in the acquisition and development of oil and natural gas properties primarily located in the Permian Basin, Mid-Continent, and Rocky Mountain regions of the United States. As of December 31, 2010, it owned interests in producing oil and natural gas properties in 370 fields in the Permian Basin, Texas Panhandle, Wyoming, Oklahoma, and several other states; operated 2,132 gross productive wells; and owned non-operated interests in 3,227 gross productive wells, as well as had proved reserves of approximately 52.8 million barrels of crude oil equivalent. Legacy Reserves GP, LLC operates as the general partner of the partnership. Legacy Reserves LP was founded in 2005 and is headquartered in Midland, Texas.
Advisors' Opinion:- [By Seth Jayson]
Legacy Reserves Lp (Nasdaq: LGCY ) is expected to report Q2 earnings around July 19. Here's what Wall Street wants to see:
The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Legacy Reserves Lp's revenues will grow 46.8% and EPS will expand 42.9%. - [By Matt DiLallo]
Companies that hedge over the long-term can end up doing very well. This is really clearly seen when looking at an oil and gas MLP like Legacy Reserves (NASDAQ: LGCY ) . The following chart does a great job of showing its annual revenues with and without the impact of its hedging program:
- [By Robert Rapier]
VNR is one of 14 companies/partnerships that are categorized as exploration and production, or ��pstream.��Other notable entries in this category include BreitBurn Energy Partners (Nasdaq: BBEP), Linn Energy (Nasdaq: LINE), Memorial Production Partners (Nasdaq: MEMP), QR Energy (NYSE: QRE), Legacy Reserves (Nasdaq: LGCY), EV Energy Partners (Nasdaq: EVEP), and Mid-Con Energy Partners (Nasdaq: MCEP).
Top 10 Cheapest Stocks For 2014: E2open Inc (EOPN)
E2open, Inc., incorporated in September 2003, is a provider of cloud-based, on-demand software solutions. The Company�� software applications allow network participants to input, access and share data and execute business processes across internal operating units and external entities. Its E2open Business Network supports operational business processes of its customers and their trading partners, including supply chain management, procurement, sales and finance functions. The E2open Business Network enables integrated planning and execution across trading partner networks. The Company offers on-demand software solutions, which enable its customers to have constant access to its solutions.
The Company houses the hardware and software in third-party facilities, and provides its customers with access to the software applications, along with data security and storage, backup, and recovery services. It invoices its customers for subscription and support in advance for annual use of its software solutions. The Company�� professional services revenue is primarily derived from fees for enabling services, such as solution consulting, solution deployment, B2B on-boarding and solution support that help its customers deploy, manage and support our solutions. These services are sold in conjunction with the sale of its on-demand software solutions or on a standalone basis. It provides professional services both on a fixed fee and a time and materials basis, and invoices its customers in advance, monthly, or upon reaching project milestones.
The Company competes with Infor, Oracle, SAP, GXS Corporation, IBM/Sterling Commerce, SPS Commerce and JDA Software Group, Inc.
Advisors' Opinion:- [By The GeoTeam]
Our recent 2013 articles on SaaS companies Selectica (SLTC), E2open (EOPN), Responsys (MKTG), Vocus (VOCS), and ExactTarget (ET) highlighted such opportunities. The average return since the inception of our coverage currently stands at around 34% (55% at their highs).
- [By Monica Gerson]
E2open (NASDAQ: EOPN) is projected to post a Q2 loss at $0.15 per share on revenue of $17.23 million.
Bank of the Ozarks (NASDAQ: OZRK) is expected to post its Q3 earnings at $0.60 per share on revenue of $69.57 million.
- [By Evan Niu, CFA]
What: Shares of E2open (NASDAQ: EOPN ) have plunged today by as much as 28% after the company reported fourth-quarter results.
So what: Non-GAAP revenue in the fourth quarter totaled $18.1 million, shy of the $19.7 million in adjusted sales that investors were expecting. The bottom line also registered a miss, with the adjusted loss of $0.06 coming in below the consensus estimate of a $0.05 per share non-GAAP net loss. CEO Mark Woodward's comments about the company adding a record number of new customers in the quarter didn't make investors feel any better.
Top 10 Cheapest Stocks For 2014: Citigroup Inc.(C)
Citigroup, Inc., a global financial services company, provides consumers, corporations, governments, and institutions with a range of financial products and services. The company operates through two segments, Citicorp and Citi Holdings. The Citicorp segment operates as a global bank for businesses and consumers with two primary businesses, Regional Consumer Banking and Institutional Clients Group. The Regional Consumer Banking business provides traditional banking services, including retail banking, and branded cards in North America, Asia, Latin America, Europe, the Middle East, and Africa. The Institutional Clients Group business provides securities and banking services comprising investment banking and advisory services, lending, debt and equity sales and trading, institutional brokerage, foreign exchange, structured products, cash instruments and related derivatives, and private banking; and transaction services consisting of treasury and trade solutions, and securiti es and fund services. The Citi Holdings segment operates Brokerage and Asset Management, Local Consumer Lending, and Special Asset Pool businesses. The Brokerage and Asset Management Business, through its 49% stake in Morgan Stanley Smith Barney joint venture and Nikko Cordial Securities, offers retail brokerage and asset management services. The Local Consumer Lending business provides residential mortgage loans, retail partner card loans, personal loans, commercial real estate, and other consumer loans, as well as western European cards and retail banking services. The Special Asset Pool business is a portfolio of securities, loans, and other assets. Citigroup Inc. has approximately 200 million customer accounts and operates in approximately 160 countries. The company was founded in 1812 and is based in New York, New York.
Advisors' Opinion:- [By Garrett Baldwin]
The FHFA has taken legal actions against 18 institutions over bad mortgage bonds in 2011, including Citigroup Inc. (NYSE: C), Bank of America Corp. (NYSE: BAC), and UBS. However, only Citigroup, General Electric Co. (NYSE: GE), and UBS have settled.
- [By John Maxfield]
Could this be the reason financial stocks are soaring today? At last check, the KBW Bank Index (DJINDICES: ^BKX ) is higher by 1.4%, and the nation's other large banks are following Bank of America's lead. JPMorgan Chase (NYSE: JPM ) is higher by 1.3%, Wells Fargo (NYSE: WFC ) by 1%, and Citigroup (NYSE: C ) by 2%.
Top 10 Cheapest Stocks For 2014: OncoSec Medical Inc (ONCS)
OncoSec Medical Incorporated, incorporated on February 8, 2008, is an emerging drug-medical device company. The Company focused on designing, developing and commercializing medical approaches for the treatment of solid cancers. In March 2011, the Company acquired from Inovio Pharmaceuticals, Inc. (Inovio) certain assets related to the use of drug-medical device combination products for the treatment of different cancers.
The Company�� acquired assets relate to certain non-deoxyribonucleic acid (DNA) vaccine technology and property relating to selective tumor ablation technologies, which it refers to as the OncoSec Medical System (OMS), a therapy which uses an electroporation device to facilitate delivery of chemotherapy agents, or nucleic acids encoding cytokines, into tumors and/or surrounding tissue for the treatment and diagnosis of various cancers. As of January 24, 2012, the Company had not generated any revenue from operations.
Advisors' Opinion:- [By James E. Brumley]
How does the old saying go? Beggars can't be choosers? Two weeks ago, yours truly penned some bullish comments regarding OncoSec Medical Inc. (OTCMKTS:ONCS). The long and short of it was, if ONCS could clear a technical ceiling around $0.36, then life would get much easier for the bulls.
- [By John Udovich]
Small cap biotech stocks AVEO Pharmaceuticals, Inc (NASDAQ: AVEO), OncoSec Medical Inc (OTCMKTS: ONCS) and MetaStat Inc (OTCBB: MTST) are focused on or are developing treatments or diagnostic technologies for metastatic cancers. In case you aren�� familiar with the term metastasis or metastatic, it�� the�spread of cancer from its primary site to other places in the body as cancer cells break away from a primary tumor, penetrate into lymphatic and blood vessels, circulate through the bloodstream and then grow in a new focus (metastasize) in normal tissues elsewhere in the body. In other words, it�� a dangerous form of cancer, but there are some small cap biotech stocks targeting it for diagnostics or treatment:
Top 10 Cheapest Stocks For 2014: Webster Financial Corp (WBS)
Webster Financial Corporation (Webster), incorporated on September 10, 1986, is a bank holding company and financial holding company. Webster�� principal asset as of December 31, 2012, was Webster Bank, National Association (Webster Bank). Webster, through Webster Bank and various subsidiaries, delivers financial services to individuals, families and businesses primarily throughout southern New England and into Westchester County, New York. Webster provides business and consumer banking, mortgage lending, financial planning, trust and investment services through 167 banking offices, 293 automated teller machines (ATMs), telephone banking, mobile banking and its Internet Website www.websterbank.com. Webster also offers equipment financing, commercial real estate lending and asset-based lending across the Northeast. Webster Bank offers health savings accounts on a nationwide basis, through its HSA Bank division and its Internet Website www.hsabank.com. Webster�� operations are managed along four business segments: Commercial Banking, Retail Banking, Consumer Finance and Other. Other includes Health Savings Accounts (HSA) and Private Banking (including Webster Financial Advisors (WFA)).
Commercial Banking
The Commercial Banking segment includes middle market, asset-based lending, commercial real estate, equipment finance, and Government and not-for-profit banking. Webster�� Commercial Banking group provides lending, deposit and cash management services to middle market companies in its franchise territory. Additionally, it serves as a primary referral source to Wealth Management and Retail Banking.
Retail Banking
Retail Banking serves consumers and small businesses primarily throughout southern New England and into Westchester County, New York, with a distribution network of 167 banking offices and 293 owned ATMs, and a full range of Internet and mobile banking services. Retail Banking includes Webster�� branch network, Consumer deposits, Busin! ess and Professional Banking (BPB), Webster Investment Services (WIS) and the Customer Care Center.
Consumer Finance
Consumer Finance offers lending solutions for consumers primarily in southern New England and Westchester County, New York. Products include: residential mortgages, home equity loans and lines of credit, unsecured personal loans as well as credit card options.
Other
Other includes HSA Bank (HSA) and Private Banking. HSA Bank is a bank custodian of health savings accounts. These accounts are provided for high deductible health plans offered by employers or directly to consumers. Private Banking provides local full relationship banking that serves high net worth clients, not-for-profit organizations and business clients for asset management, trust, loan and deposit products and financial planning services.
Subsidiaries of Webster Financial Corporation
Webster�� direct subsidiaries as of December 31, 2012 included Webster Bank, Fleming, Perry & Cox, Inc., and Webster Licensing, LLC. Webster also owns all of the outstanding common stock of Webster Statutory Trust, an unconsolidated financial vehicle that has issued or may in the future issue trust preferred securities. On July 18, 2012, the Company completed the redemption at par of all the outstanding principal amount of Webster Capital Trust IV fixed to floating-rate trust preferred securities. Webster Bank's direct subsidiaries include Webster Mortgage Investment Corporation, Webster Business Credit Corporation (WBCC) and Webster Capital Finance, Inc. (WCF). Webster Bank is the primary source of retail activity within the consolidated Company. Webster Bank is the primary source of retail activity within the consolidated group. Webster Bank provides banking services through 167 banking offices, 293 owned ATMs, telephone banking, mobile banking and its Internet websites. Residential mortgage origination activity is conducted through Webster Bank. Webster Mortgage! Investme! nt Corporation is a passive investment subsidiary whose primary function is to provide servicing on passive investments, such as residential real estate and commercial mortgage real estate loans transferred from Webster Bank. Various commercial lending products are provided through Webster Bank and its subsidiaries to clients within the region from Westchester County, NY to Boston, MA. WBCC provides asset-based lending services. WCF provides equipment financing for end users of equipment. Additionally, Webster Bank has various other subsidiaries that are not significant to the consolidated Company.
Advisors' Opinion:- [By Monica Gerson]
Webster Financial (NYSE: WBS) is projected to report its Q3 earnings at $0.49 per share on revenue of $149.73 million.
Wells Fargo & Company (NYSE: WFC) is estimated to report its Q3 earnings at $0.97 per share on revenue of $20.97 billion.
- [By Marc Bastow]
Bank holding and financial company Webster Bank (WBS) raised its quarterly dividend 33% to 20 cents per share payable June 16 to shareholders of record June 2.
WBS Dividend Yield: 2.63%
Top 10 Cheapest Stocks For 2014: Keryx Biopharmaceuticals Inc.(KERX)
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, together with its subsidiaries, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment cancer and renal disease. The company?s products under development include KRX-0401 (perifosine), an oral anti-cancer agent that inhibits Akt activation in the phosphoinositide 3-kinase (PI3K) pathway, as well as affects other pathways associated with programmed cell death, cell growth, cell differentiation, and cell survival. Its KRX-0401 is in Phase III clinical development stage for the treatment of refractory advanced colorectal cancer and multiple myeloma, as well as in Phase I and Phase II clinical development stages for the treatment of other tumor types. The company is also developing Zerenex (ferric citrate), an oral, ferric iron-based compound that is in Phase III clinical development for the treatment of hyperphosphatemia in patients with end-stage renal disease o n dialysis. Keryx Biopharmaceuticals, Inc. has commercial license agreements with Zentaris AG for the development of KRX-0401; Panion & BF Biotech, Inc. for the development and marketing of Zerenex; and Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. The company was founded in 1997 and is based in New York, New York.
Advisors' Opinion:- [By gurujx]
Keryx Biopharmaceuticals Inc. (KERX): CFO James F. Oliviero III Sold 109,500 Shares
CFO�James F. Oliviero III�sold 109,500 shares of KERX stock on 12/30/2013 at the average price of $12.64. James F. Oliviero III owns at least 476,429 shares after this. The price of the stock has decreased by 3.32% since.
- [By Selena Maranjian]
Among holdings in which D.E. Shaw increased its stake was Keryx Pharmaceuticals (NASDAQ: KERX ) , which is up more than 350% over the past year. Bulls are excited about its kidney-disease drug, Zerenex. Results for the drug have been promising, and the company is looking to expand its applications and approvals. Not as promising is that the company's experimental colorectal cancer drug perifosine recently posted disappointing results, sending the stock down some. A plus for the company is its ample cash, which should support its drive toward approvals and eventual profits.
- [By Jake L'Ecuyer]
Leading and Lagging Sectors
Healthcare sector moved up 0.39 percent, with Keryx Biopharmaceuticals (NASDAQ: KERX) moving up 15 percent to gain the top spot. Top gainers in the sector included China Biologic Products (NASDAQ: CBPO), with shares up 7.4 percent, and Laboratory Corp. of America Holdings (NYSE: LH), with shares up 5.5 percent. - [By MONEYMORNING]
Case in point: Keryx Biopharmaceuticals (Nasdaq: KERX) is a small biotech (market cap: $1.29B) with an experimental drug, Zerenex, that treats elevated phosphate levels and iron deficiency anemia in patients on dialysis for advanced chronic kidney disease (CKD).
Top 10 Cheapest Stocks For 2014: Varian Medical Systems Inc.(VAR)
Varian Medical Systems, Inc. designs, manufactures, sells, and services equipment and software products for treating cancer with radiotherapy, stereotactic radiotherapy, stereotactic body radiotherapy, stereotactic radiosurgery, and brachytherapy worldwide. Its Oncology Systems segment offers products, such as linear accelerators, brachytherapy afterloaders, treatment simulation and verification equipment, and accessories; and information management, treatment planning, and image processing software. This segment serves university research and community hospitals, private and governmental institutions, healthcare agencies, doctors? offices, and cancer care clinics. The company?s X-ray Products segment provides x-ray tubes for use in a range of applications, including computed tomography scanning, radiographic or fluoroscopic imaging, mammography, special procedures, and industrial applications; and flat panel digital image detectors for filmless x-ray imaging. It sells t hese products to imaging systems original equipment manufacturers that incorporate them into their medical diagnostic, dental, veterinary, and industrial imaging systems; independent service companies; and directly to end-users. The company also designs, manufactures, sells, and services Linatron x-ray accelerators, imaging processing software, and image detection products for security and inspection purposes, such as cargo screening at ports and borders, and nondestructive examination in various applications. In addition, it develops products and systems for delivering proton therapy; and technologies in the areas of digital X-ray imaging technology, volumetric and functional imaging, improved X-ray sources, and technology for security and cargo screening applications. The company was formerly known as Varian Associates, Inc. and changed its name to Varian Medical Systems, Inc. in April 1999. Varian Medical Systems, Inc. was founded in 1948 and is headquartered in Palo Alto , California.
Advisors' Opinion:- [By Holly LaFon]
Varian Medical Systems (VAR) has been a staple in our portfolio since the fall of 2005. The stock has rebounded smartly, up +31% from its April 2013 lows through the first quarter. Varian continues to be the global market share and technological leader in the radiation oncology business. Unfortunately, the incidence of cancer continues its deadly growth. In the U.S. alone, the American Cancer Society projects that some 1.7 million people will be diagnosed with cancer. Expectations of new cancer cases around the world are approaching 25 million over the next three decades. Of these new cases, approximately two-颅��hirds will be treated with some sort of radiation therapy. Varian has been at the forefront of linear particle accelerator since the late 1940's. Today the Company's installed base numbers over 7,300 LINACS across the globe ��a 60% market share. As impressive as that may sound, the availability of state-颅��f-颅��he-颅��rt radiation therapy (radiosurgery and proton therapy) outside of the U.S. is woefully low. The developed world has access to 35 to 110 LINACS per million people over the age of 65. In the U.S., it's 110 LINACS per million. Western Europe and Japan is 35 to 65 per million. In India, Africa, Eastern Europe and Southeast Asia there are between 1 and 20 machines per million. In China there is less than 10 machines per million. Complementing the Company's long-颅��erm growth opportunity in radiation therapy is the secular trend in the "digitization of radiology," which is a key driver of their lucrative software and flat-颅��anel services business, plus their X-颅��ay tube replacement business that sells into the installed base of competing LINACS. The Company's initiatives to drive greater productivity continue to bear fruit. In 2013 sales per employee increased 14% and operating income per employee increased 20% over 2012 levels. Such productivity has helped the Company offset the continuing losses as they rollout their prot
- [By Seth Jayson]
Basic guidelines
In this series, I examine inventory using a simple rule of thumb: Inventory increases ought to roughly parallel revenue increases. If inventory bloats more quickly than sales grow, this might be a sign that expected sales haven't materialized. Is the current inventory situation at Varian Medical Systems (NYSE: VAR ) out of line? To figure that out, start by comparing the company's inventory growth to sales growth. How is Varian Medical Systems doing by this quick checkup? At first glance, not so great. Trailing-12-month revenue increased 7.2%, and inventory increased 13.0%. Comparing the latest quarter to the prior-year quarter, the story looks decent. Revenue grew 6.7%, and inventory increased 13.0%. Over the sequential quarterly period, the trend looks healthy. Revenue grew 13.3%, and inventory grew 0.6%.
No comments:
Post a Comment